iSpecimen (ISPC) EBITDA (2020 - 2026)

iSpecimen (ISPC) has reported EBITDA for 7 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 53.06% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$11.4 million (down 1.01% YoY), while the FY2025 annual figure was -$10.5 million, up 16.09% from the prior year.
• EBITDA came in at -$2.5 million for Q1 2026 at iSpecimen, up from -$5.0 million in the prior quarter.
• The five-year high for EBITDA was -$1.0 million in Q2 2025, with the low at -$6.0 million in Q4 2024.
• Average EBITDA over 5 years is -$2.8 million, with a median of -$2.5 million recorded in 2023.
• Across the five-year window, EBITDA plunged 150.19% in 2022 and jumped 50.35% in 2025, its largest moves.
• Year by year, EBITDA stood at -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then sank by 110.62% to -$6.0 million in 2024, then rose by 17.29% to -$5.0 million in 2025, then surged by 49.24% to -$2.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.5 million, -$5.0 million, and -$2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.